On Nov. 30, 2020, Innovation Pharmaceuticals announced additional independent preliminary laboratory research suggests Brilacidin, the Company’s flagship defensin mimetic, had the potential to treat other endemic human coronaviruses (H-CoVs), such as those causing common colds, and not just SARS-CoV-2, the novel coronavirus responsible for the ongoing global COVID-19 pandemic.